<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427295</url>
  </required_header>
  <id_info>
    <org_study_id>CSMS995BKR08T</org_study_id>
    <nct_id>NCT02427295</nct_id>
  </id_info>
  <brief_title>Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues</brief_title>
  <acronym>acromegaly</acronym>
  <official_title>Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term (up to 3 years) clinical and hormonal outcomes in acromegalic patients with treated
      surgery with or without long acting somatostatin analogues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are diagnosed with acromegaly with a GH-secreting pituitary adenoma receiving
      TSA at the Asan Medical Center (Seoul, Korea) from Aug 2013 to Aug 2015 will be recruited.

      The eligible patient population will consist of 30 adult, male and female patient with Age 18
      or older.

        -  Number of patients by treatment group: Surgical treatment only = 15, Surgery with
           medical treatment = 15

        -  Number of Centers: 1 (single center)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who achieved normalization of fasting serum IGF-1 (age and sex matched)</measure>
    <time_frame>Change from within 3days post-operative in fasting serum IGF-1at 36 months post-operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The time taken to IGF-1 normalization in each group.</measure>
    <time_frame>Change from within 3days post-operative in IGF-1 normalization at 36 months post-operative months post-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GH suppressive responses (a nadir GH &lt; 0.4 ng/ml) to oral glucose</measure>
    <time_frame>Change from Pre-operative in GH suppressive responses (a nadir GH &lt; 0.4 ng/ml) at 36 months post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptom and sign with AcroQoL questionnaire</measure>
    <time_frame>Change from Pre-operative in Clinical symptom and sign with AcroQoL questionnaire at 36 months post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality and disturbance with written questionnaire</measure>
    <time_frame>Change from Pre-operative in Sleep quality and disturbance with written questionnaire at 24 months post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose , postprandial glucose</measure>
    <time_frame>Change from pre-operative in fasting glucose , postprandial glucose at 36 months post-operative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>Change from pre-operative in insulin at 36 months post-operative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>change from pre-operative in HbA1c at 36 months post-operative.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Group 2: Surgery + Medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI : residual tumor 6 months post-op : IGF-1 &gt;600 ng/ml
medical treatment : Sandostatin (Octreotide Acetate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 : Rescue group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gruop1 : Surgery only group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>MRI : without residual tumor 6months post-operation
and IGF-1 &lt;600ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandostatin (Octreotide Acetate)</intervention_name>
    <description>For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:
Dose: Sandostatin LARÂ® 20mg per 4 weeks for 3 months -&gt; If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.
Frequency: every 4 weeks.
Route of administration: IM injection.</description>
    <arm_group_label>Group 2: Surgery + Medical treatment</arm_group_label>
    <other_name>Sandostatin LAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older.

          2. Patients diagnosed with acromegaly with GH-secreting pituitary adenoma on sellar MRI,
             meeting the biochemical criteria outlined above (refer to 1. Diagnosis of acromegaly)
             and with typical acromegalic features.

          3. No prior use of somatostatin analogues.

          4. Adequate hepatic and renal function

          5. Provision of a signed written informed consent

        Exclusion Criteria:

          1. Severe co-morbid illness such as untreatable other malignancy and/or active
             infections.

          2. Pregnant or lactating women

          3. Hypersensitivity to Sandostatin or any component of the formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>minseon Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>minseon Kim, PhD</last_name>
    <phone>82-2-3010-3245</phone>
    <email>mskim@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>heesun Park, college</last_name>
    <phone>82-2-3010-4135</phone>
    <email>guccienvy2@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>minseon Kim, PhD</last_name>
      <phone>82-2-3010-3245</phone>
      <email>mskim@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>min seon kim</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

